STOCK TITAN

Schedule 13G: Wellington's 50.1M-Share Position in ZLAB Disclosed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Wellington Management and affiliates reported beneficial ownership of 50,084,792 shares of Zai Lab Ltd. common stock, representing 4.51% of the class as of the report. The filing is a Schedule 13G 0 sole voting or dispositive power, 42,744,773 shares of shared voting power and 50,084,792 shares of shared dispositive power. The securities are owned of record by clients of the Wellington Investment Advisers and the filing states no client is known to own more than 5% of the class. The document lists the issuer's principal executive office in Shanghai and is certified and signed by a Wellington regulatory analyst on 08/12/2025.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: A major asset manager discloses a 4.51% passive stake in Zai Lab held for clients; no single client exceeds 5%.

The Schedule 13G/A shows Wellington Management Group LLP and affiliated entities collectively beneficially own 50,084,792 shares of Zai Lab common stock with shared voting power of 42,744,773. The filing indicates these holdings are client-owned and held in the ordinary course of business, consistent with a passive investor disclosure rather than an activist intent. For investors, this clarifies large institutional exposure but does not signal a change in control or a proxy contest given the sub-5% client concentration and the use of a 13G filing.

TL;DR: Ownership disclosure improves transparency; classification as 13G implies passive intent and limited governance impact.

The filing identifies multiple Wellington entities and investment adviser subsidiaries that collectively hold the position and confirms that no client is known to control more than 5% of the class. Shared voting and dispositive powers are disclosed, with no sole control reported. From a governance perspective, this is routine institutional reporting: it documents material institutional ownership but contains no indication of coordinated governance action or control-seeking behavior.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:08/12/2025

FAQ

What stake does Wellington report in Zai Lab (ZLAB)?

Wellington and affiliates report beneficial ownership of 50,084,792 shares, equal to 4.51% of Zai Lab common stock.

Does Wellington have sole voting or dispositive power over the ZLAB shares?

No. The filing reports 0 shares with sole voting power and 0 shares with sole dispositive power; voting and dispositive power are shared.

Are the ZLAB shares held for Wellington's clients or the firm?

The securities are owned of record by clients of the Wellington Investment Advisers and are held in the ordinary course of business.

Does any Wellington client hold more than 5% of Zai Lab according to the filing?

No. The filing states no client is known to have the right to receive dividends or proceeds with respect to more than 5% of the class.

When was the Schedule 13G/A signed and who signed it?

The filing is signed by Taisia Lowe, Regulatory Analyst, on 08/12/2025.
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Latest SEC Filings

ZLAB Stock Data

2.04B
106.96M
1.74%
42.53%
4.26%
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI